USA - NASDAQ:RCEL - US05380C1027 - Common Stock
The current stock price of RCEL is 3.66 USD. In the past month the price decreased by -28.38%. In the past year, price decreased by -64.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.49 | 401.96B | ||
| AMGN | AMGEN INC | 13.39 | 157.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.27B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.93 | 108.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.34 | 69.37B | ||
| ARGX | ARGENX SE - ADR | 90.81 | 51.50B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.80B | ||
| NTRA | NATERA INC | N/A | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 260 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
AVITA MEDICAL INC
28159 Avenue Stanford, Suite 220
Valencia California CALIFORNIA 91355 US
CEO: Michael Perry
Employees: 260
Phone: 16613679170
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 260 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
The current stock price of RCEL is 3.66 USD. The price decreased by -3.43% in the last trading session.
RCEL does not pay a dividend.
RCEL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
AVITA MEDICAL INC (RCEL) operates in the Health Care sector and the Biotechnology industry.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RCEL.
The Revenue of AVITA MEDICAL INC (RCEL) is expected to grow by 14.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a fundamental rating of 3 / 10 to RCEL. Both the profitability and financial health of RCEL have multiple concerns.
Over the last trailing twelve months RCEL reported a non-GAAP Earnings per Share(EPS) of -1.97. The EPS decreased by -1.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
13 analysts have analysed RCEL and the average price target is 8.98 USD. This implies a price increase of 145.25% is expected in the next year compared to the current price of 3.66.
For the next year, analysts expect an EPS growth of 46.94% and a revenue growth 14.01% for RCEL